Epilepsy treatment as a predeterminant of psychosocial ill health

Epilepsy and Behavior

Volumn 15, Issue 2 SUPPL. 1, 2009, Pages

  Perucca, Piero ^a   Gilliam, Frank G ^a   Schmitz, Bettina ^b  

^a Howard Hughes Medical Institute   (United States)

^b VIVANTES HOSPITAL   (Germany)

Author keywords

Anti epileptic Drug; Epilepsy; Quality of Life; Side effects

Indexed keywords

ANTICONVULSIVE AGENT;

ANXIETY; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; COUGHING; DEPRESSION; DISEASE COURSE; DYSPEPSIA; DYSPNEA; EMPLOYMENT; EMPLOYMENT DISCRIMINATION; EPILEPSY; GOOD CLINICAL PRACTICE; HEADACHE; HUMAN; MEDICAL RESEARCH; MEMORY DISORDER; MYALGIA; NAUSEA AND VOMITING; NEUROSURGERY; PARESTHESIA; PHYSICAL CAPACITY; PSYCHOLOGICAL WELL BEING; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; SELF CONCEPT; SIDE EFFECT; SOCIAL ASPECT; SOCIAL DISCRIMINATION; SORE THROAT; STIGMA; TEMPORAL LOBECTOMY; TREATMENT OUTCOME; VAGUS NERVE STIMULATION; VOICE CHANGE;

ANTICONVULSANTS; EPILEPSY; HEALTH STATUS; HUMANS; NEUROSURGERY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIAL ADJUSTMENT; VAGUS NERVE STIMULATION;

EID: 66149096589     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.03.016     Document Type: Article

References (68)

1. Baker G.A., et al. Quality of life of people with epilepsy: a European study. Epilepsia 38 (1997) 353-362
2. Kanner A.M. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry 54 (2003) 388-398
3. Hermann B.P., et al. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol 60 (2006) 80-87
4. Aldenkamp A.P., and Bodde N. Behaviour, cognition and epilepsy. Acta Neurol Scand Suppl 182 (2005) 19-25
5. Sillanpaa M., Haataja L., and Shinnar S. Perceived impact of childhood-onset epilepsy on quality of life as an adult. Epilepsia 45 (2004) 971-977
6. Sillanpaa M., and Shinnar S. Obtaining a driver's license and seizure relapse in patients with childhood-onset epilepsy. Neurology 64 (2005) 680-686
7. Gilliam F., et al. Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia 38 (1997) 233-236
8. Tomson T., et al. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 46 Suppl. 11 (2005) 54-61
9. Zaccara G., Franciotta D., and Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48 (2007) 1223-1244
10. Gilliam F., Carter J., and Vahle V. Tolerability of antiseizure medications: implications for health outcomes. Neurology 63 10, Suppl. 4 (2004) S9-S12
11. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
12. Dlugos D.J., et al. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 57 (2001) 2259-2264
13. Cramer J.A., et al. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40 (1999) 590-600
14. Gilliam F.G., et al. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 62 (2004) 23-27
15. Wiebe S., et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 345 (2001) 311-318
16. Sperling M.R., et al. Temporal lobectomy for refractory epilepsy. JAMA 276 (1996) 470-475
17. Handforth A., et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 51 (1998) 48-55
18. Renfroe J.B., and Wheless J. Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy. Neurology 59 6, Suppl. 4 (2002) S26-S30
19. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a multicenter survey of clinical practice. Epilepsia 1986;27:323-30.
20. Mattson R.H., et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313 (1985) 145-151
21. Mattson R.H., Cramer J.A., Collins J.F., and for the Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 327 (1992) 765-771
22. French J.A., et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60 (2003) 1631-1637
23. Schachter S.C., et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 52 (1999) 732-737
24. Uijl S.G., et al. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure 15 (2006) 242-248
25. Perucca E., and Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 19 (2005) 897-908
26. Karceski S.C. Seizure medications and their side effects. Neurology 69 (2007) E27-E29
27. Leidy N.K., et al. Seizure frequency and the health-related quality of life of adults with epilepsy. Neurology 53 (1999) 162-166
28. Birbeck G.L., et al. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 43 (2002) 535-538
29. Markand O.N., et al. Health-related quality of life outcome in medically refractory epilepsy treated with anterior temporal lobectomy. Epilepsia 41 (2000) 749-759
30. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 58 8, Suppl. 5 (2002) S9-S20
31. Boylan L.S., et al. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 62 (2004) 258-261
32. Jacoby A., et al. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology 68 (2007) 1188-1196
33. O'Donoghue M.F., et al. Assessing the psychosocial consequences of epilepsy: a community-based study. Br J Gen Pract 49 (1999) 211-214
34. Gilliam F.G., et al. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 5 (2006) 399-405
35. Engel Jr. J., et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 60 (2003) 538-547
36. Arruda F., et al. Mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removal. Ann Neurol 40 (1996) 446-450
37. Gilliam F., et al. Epilepsy surgery outcome: comprehensive assessment in children. Neurology 48 (1997) 1368-1374
38. McLachlan R.S., et al. Health-related quality of life and seizure control in temporal lobe epilepsy. Ann Neurol 41 (1997) 482-489
39. Spencer S.S., et al. Health-related quality of life over time since resective epilepsy surgery. Ann Neurol 62 (2007) 327-334
40. Vickrey B.G., et al. Outcomes in 248 patients who had diagnostic evaluations for epilepsy surgery. Lancet 346 (1995) 1445-1449
41. Tellez-Zenteno J.F., et al. Long-term outcomes in epilepsy surgery: antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain 130 Pt. 2 (2007) 334-345
42. Elger C.E., Helmstaedter C., and Kurthen M. Chronic epilepsy and cognition. Lancet Neurol 3 (2004) 663-672
43. Martin R.C., et al. Risk to verbal memory following anterior temporal lobectomy in patients with severe left-sided hippocampal sclerosis. Arch Neurol 59 (2002) 1895-1901
44. Helmstaedter C., et al. Chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy. Ann Neurol 54 (2003) 425-432
45. Langfitt J.T., et al. Worsening of quality of life after epilepsy surgery: effect of seizures and memory decline. Neurology 68 (2007) 1988-1994
46. Sawrie S.M., et al. Subjective versus objective memory change after temporal lobe epilepsy surgery. Neurology 53 (1999) 1511-1517
47. Penry J.K., and Dean J.C. Prevention of intractable partial seizures by intermittent vagal stimulation in humans: preliminary results. Epilepsia 31 Suppl. 2 (1990) S40-S43
48. Uthman B.M., et al. Efficacy and safety of vagus nerve stimulation in patients with complex partial seizures. Epilepsia 31 Suppl. 2 (1990) S44-S50
49. Uthman B.M., et al. Treatment of epilepsy by stimulation of the vagus nerve. Neurology 43 (1993) 1338-1345
50. Morris III G.L., Mueller W.M., and for the Vagus Nerve Stimulation Study Group E01-E05. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. Neurology 53 (1999) 1731-1735
51. DeGiorgio C.M., et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 41 (2000) 1195-1200
52. Uthman B.M., et al. Effectiveness of vagus nerve stimulation in epilepsy patients: a 12-year observation. Neurology 63 (2004) 1124-1126
53. The Vagus Nerve Stimulation Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 1995;45:224-30.
54. Physician's Manual NeuroCybernetic Prosthesis System NCP Pulse Generator Models 100 and 101. Houston: Cyberonics, Inc.; 2000.
55. Schachter S.C. Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology 59 6, Suppl. 4 (2002) S15-S20
56. Tatum W.O., et al. Ventricular asystole during vagus nerve stimulation for epilepsy in humans. Neurology 52 (1999) 1267-1269
57. Ben-Menachem E., et al. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. Neurology 52 (1999) 1265-1267
58. Cramer J.A. Exploration of changes in health-related quality of life after 3 months of vagus nerve stimulation. Epilepsy Behav 2 (2001) 460-465
59. McLachlan R.S., et al. Quality of life after vagus nerve stimulation for intractable epilepsy: is seizure control the only contributing factor?. Eur Neurol 50 (2003) 16-19
60. Ergene E., Behr P.K., and Shih J.J. Quality-of-life assessment in patients treated with vagus nerve stimulation. Epilepsy Behav 2 (2001) 284-287
61. Tatum W.O., et al. Vagus nerve stimulation and drug reduction. Neurology 56 (2001) 561-563
62. Labar D.R. Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study. Neurology 59 6, Suppl. 4 (2002) S38-S43
63. Rush A.J., et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 47 (2000) 276-286
64. Rush A.J., et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 58 (2005) 355-363
65. Clark K.B., et al. Enhanced recognition memory following vagus nerve stimulation in human subjects. Nat Neurosci 2 (1999) 94-98
66. Elger G., et al. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 42 (2000) 203-210
67. Hoppe C., et al. Self-reported mood changes following 6 months of vagus nerve stimulation in epilepsy patients. Epilepsy Behav 2 (2001) 335-342
68. Helmstaedter C., Hoppe C., and Elger C.E. Memory alterations during acute high-intensity vagus nerve stimulation. Epilepsy Res 47 (2001) 37-42